Stavudine was administered (15 mg/kg of body weight) intravenously and orally to two monkeys in a randomized crossover study. Plasma and urine samples were analyzed for stavudine by high-performance liquid chromatography, and pharmacokinetic parameters were derived by a noncompartmental method. Total body clearance of stavudine was 0.64 liters/h/kg, with a steady-state volume of distribution of 0.68 liters/kg, a terminal half-life of 0.83 h, a urinary recovery of 44%, and an oral bioavailability of 80%. These values were reasonably similar to those reported for patients with AIDS or AIDS-related complex.
and about 60 to 80% of a dose is cleared from the body primarily by metabolism to the 5'-O-glucuronide. Of the animals investigated, the monkey has been identified as an appropriate animal model for zidovudine pharmacokinetics in humans (3, 5, 10, 11, 18) compared with other animals (11, 18, 19, 37) . Likewise, the monkey appears to be an acceptable model for didanosine pharmacokinetics in humans (33) .
Of several dideoxynucleoside analogs with in vitro antihuman immunodeficiency virus activity, stavudine has emerged as a potent agent which is being evaluated currently in clinical trials for the treatment of human immunodeficiency virus infection (2, 14, 15, 32) . The pharmacokinetics of stavudine in humans (13, 22, 24) and various animal species (6, 7, 35, 36, 38) have been reported previously.
Studies with rodents have shown that the t1l2 of stavudine ranged from 0.3 to 0.6 h, the urinary recovery was about 70 to 80%, and the oral bioavailability was in the range of 80 to 95%. Although the t1l2 of stavudine in rhesus monkeys (0.9 to 1.4 h) is comparable to that in humans (13, 22, 24) , interestingly, its absolute bioavailability is only 42% (versus 80 to 90% in humans) and the fractional urinary elimination of unchanged drug has not been reported. Therefore, the pharmacokinetics, oral bioavailability, and urinary excretion of stavudine in cynomolgus monkeys were evaluated to determine whether it is an appropriate model for stavudine pharmacokinetics in humans.
Two young adult male cynomolgus monkeys weighing 2.1 kg were used in this study, after approval from the followed by ca. 10 ml of water to wash the test compound through the tube. The animals were made to fast overnight before dosing and during the period up to 3 h after dosing. The animals were given 20 ml of water (via a nasogastric tube) every hour for the next 6 h. During the experimental period (24 h), animals were placed in metabolism cages and primate restraining devices were used to facilitate blood sample collection.
Blood samples (1 ml (21, 23) . Plasma and urine samples were analyzed in one analytical session each. The within-day precision values for the quality control samples were less than 10% (coefficient of variation). The accuracy, calculated as (observed concentration/nominal concentration) x 100, of quality control samples was within 9%. Data acquisition and processing were done by a previously described method (16) .
The pharmacokinetic parameters of stavudine were calculated by a noncompartmental method (17, 34) . By using a weighting factor of 1, the terminal slope, K, was determined by log-linear regression of at least the terminal three datum points, which yielded a minimum mean square error. The following pharmacokinetic parameters were derived by previously reported equations (17, 34) : terminal t1l2, area under the concentration in plasma-time curve from time zero to infinity (AUC), total body clearance (CL), renal clearance (CLR), steady-state volume of distribution (Vsa). The peak concentration in plasma, the time to peak concentration in plasma, and the amount of drug excreted in the urine as a percentage of the dose (UR) were obtained directly from experimental observations. The oral bioavailability of stavudine was calculated as FAUC = AUCpJAUCiv and FUR = UR.PJUR vi where po and iv represent the oral and i.v. routes of administration.
Stavudine concentrations in plasma-time profiles after i.v. and oral administration of a 15-mg/kg dose to two monkeys are depicted in Fig. 1 [4-14C] stavudine per kg to three monkeys, approximately 48 and 0.1% of the radioactivity administered were recovered in urine and feces, respectively, in 30 days. The urinary recovery of stavudine was identical to that reported in the initial study; in addition to unchanged drug, three metabolites were detected: thymine (1%), ,-aminoisobutyric acid (2%), and an unidentified metabolite (1%). The sum of the three metabolites and unchanged drug accounted for virtually all of the radioactivity in the urine (36a). Although the fate of the remainder of stavudine in monkeys is unclear, it is speculated that, similar to thymidine (30), the unrecovered portion of the stavudine dose is salvaged and incorporated into endogenous macromolecules. Further work on metabolism and excretion is essential to elucidate fully the metabolic fate of stavudine in monkeys. 
